SEC Form 4 · accession 0000899243-17-011267
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yoram Palti
Officer — Chief Technology Officer · Director
Period of report
Apr 27, 2017
Accepted (ET)
May 1, 2017 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Apr 27, 2017 | S | 4,000 | $11.205 | D | 103,825 | D | |
| Ordinary SharesF2 | Apr 28, 2017 | S | 4,000 | $11.29 | D | 99,825 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On April 27, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.70 to $11.60. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F2On April 28, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Professor Palti, Professor Palti sold 4,000 shares in multiple trades at prices ranging from $10.65 to $11.60. The price reported above reflects the weighted average sale price. Professor Palti hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.